ABT ABBOTT LABORATORIES
Pharmaceutical Preparations · NYSE · SEC CIK 1800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-66.4%
TTM EPS YoY-66.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR-3.1%
Margins
Gross margin56.9%
Operating margin13.8%
Net margin9.7%
FCF margin14.0%
EBITDA margin17.0%
Returns
ROE9.2%
ROA4.9%
ROIC (approx.)7.1%
Asset turnover0.50x
Leverage & solvency
Liabilities / assets52.3%
Debt / equity0.61x
Current ratio1.45x
Interest coverage6.68x
Cash quality & payout
Operating cash flow / net income1.88x
Accruals ratio-4.3%
Payout ratio92.0%
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B |
| R&D expense | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B |
| SG&A expense | $12.33B | $11.70B | $10.95B | $11.25B | $11.32B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B |
| Interest expense | $493.00M | $559.00M | $637.00M | $558.00M | $533.00M |
| Pretax income | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B |
| Income tax | $1.94B | -$6.39B | $941.00M | $1.37B | $1.14B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| EBITDA | $9.49B | $8.16B | $7.75B | $9.62B | $9.92B |
| EPS (basic) | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 |
| EPS (diluted) | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 |
| Dividends declared per share | 2.40 | 2.24 | 2.08 | 1.92 | — |
| Weighted avg. shares (diluted) | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B |
| Balance sheet | |||||
| Cash & equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B |
| Short-term investments | $417.00M | $351.00M | $383.00M | $288.00M | $450.00M |
| Receivables | $7.93B | $6.92B | $6.57B | $6.22B | $6.49B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B |
| Current assets | $26.00B | $23.66B | $22.67B | $25.22B | $24.24B |
| PP&E, net | $11.82B | $10.66B | $10.15B | $9.16B | $8.96B |
| Goodwill | $24.04B | $23.11B | $23.68B | $22.80B | $23.23B |
| Intangibles | $5.53B | $6.65B | $8.81B | $10.45B | $12.74B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B |
| Current liabilities | $16.50B | $14.16B | $13.84B | $15.49B | $13.11B |
| Short-term debt | $3.03B | $1.50B | $1.08B | $2.25B | $0 |
| Long-term debt | $9.90B | $12.62B | $13.60B | $14.52B | $17.30B |
| Total debt | $12.93B | $14.12B | $14.68B | $16.77B | $17.30B |
| Total liabilities | $33.94B | $33.51B | $34.39B | $37.53B | $39.17B |
| Shareholders' equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B |
| Net debt | $4.41B | $6.51B | $7.78B | $6.89B | $7.50B |
| Cash flow statement | |||||
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B |
| Capital expenditure | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -$2.01B |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -$5.49B |
| Depreciation & amortization | $1.43B | $1.34B | $1.28B | $1.25B | $1.49B |
| Stock-based compensation | $664.00M | $673.00M | $644.00M | $685.00M | $640.00M |
| Dividends paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B |
| Share buybacks | $893.00M | $1.29B | $1.23B | $3.79B | $2.30B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.